Immune checkpoint inhibitors (ICI) such as Nivolumab, Atezolizumab, Pembrolizumab, and Durvalumab, which are now widely used for the treatment of lung cancer, block PD1/PDL-1 binding and thereby enable recognition of tumor cells by activated CD8+ T cells. This evidence concerns the gene PDCD1 and lung carcinoma.